vs
Side-by-side financial comparison of Astrana Health, Inc. (ASTH) and BeOne Medicines Ltd. (ONC). Click either name above to swap in a different company.
BeOne Medicines Ltd. is the larger business by last-quarter revenue ($1.5B vs $950.5M, roughly 1.6× Astrana Health, Inc.). BeOne Medicines Ltd. runs the higher net margin — 4.4% vs 0.7%, a 3.7% gap on every dollar of revenue. On growth, Astrana Health, Inc. posted the faster year-over-year revenue change (42.9% vs 32.8%). BeOne Medicines Ltd. produced more free cash flow last quarter ($379.8M vs $-6.0M). Over the past eight quarters, Astrana Health, Inc.'s revenue compounded faster (53.3% CAGR vs 41.2%).
Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.
BeOne Medicines Ltd.ONCEarnings & Financial Report
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
ASTH vs ONC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $950.5M | $1.5B |
| Net Profit | $6.6M | $66.5M |
| Gross Margin | — | 90.5% |
| Operating Margin | 1.9% | 12.4% |
| Net Margin | 0.7% | 4.4% |
| Revenue YoY | 42.9% | 32.8% |
| Net Profit YoY | 184.4% | 143.8% |
| EPS (diluted) | $0.12 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $950.5M | $1.5B | ||
| Q3 25 | $956.0M | $1.4B | ||
| Q2 25 | $654.8M | $1.3B | ||
| Q1 25 | $620.4M | $1.1B | ||
| Q4 24 | $665.2M | $1.1B | ||
| Q3 24 | $478.7M | $1.0B | ||
| Q2 24 | $486.3M | $929.2M | ||
| Q1 24 | $404.4M | $751.7M |
| Q4 25 | $6.6M | $66.5M | ||
| Q3 25 | $373.0K | $124.8M | ||
| Q2 25 | $9.4M | $94.3M | ||
| Q1 25 | $6.7M | $1.3M | ||
| Q4 24 | $-7.8M | $-151.9M | ||
| Q3 24 | $16.1M | $-121.3M | ||
| Q2 24 | $19.2M | $-120.4M | ||
| Q1 24 | $14.8M | $-251.2M |
| Q4 25 | — | 90.5% | ||
| Q3 25 | — | 86.1% | ||
| Q2 25 | — | 87.5% | ||
| Q1 25 | — | 85.2% | ||
| Q4 24 | — | 85.8% | ||
| Q3 24 | — | 83.0% | ||
| Q2 24 | — | 85.1% | ||
| Q1 24 | — | 83.4% |
| Q4 25 | 1.9% | 12.4% | ||
| Q3 25 | 2.0% | 11.5% | ||
| Q2 25 | 3.1% | 6.7% | ||
| Q1 25 | 3.3% | 1.0% | ||
| Q4 24 | 0.1% | -7.0% | ||
| Q3 24 | 5.9% | -12.0% | ||
| Q2 24 | 6.2% | -11.5% | ||
| Q1 24 | 7.5% | -34.8% |
| Q4 25 | 0.7% | 4.4% | ||
| Q3 25 | 0.0% | 8.8% | ||
| Q2 25 | 1.4% | 7.2% | ||
| Q1 25 | 1.1% | 0.1% | ||
| Q4 24 | -1.2% | -13.5% | ||
| Q3 24 | 3.4% | -12.1% | ||
| Q2 24 | 3.9% | -13.0% | ||
| Q1 24 | 3.7% | -33.4% |
| Q4 25 | $0.12 | $0.05 | ||
| Q3 25 | $0.01 | $0.08 | ||
| Q2 25 | $0.19 | $0.06 | ||
| Q1 25 | $0.14 | $0.00 | ||
| Q4 24 | $-0.14 | $-0.10 | ||
| Q3 24 | $0.33 | $-0.09 | ||
| Q2 24 | $0.40 | $-0.09 | ||
| Q1 24 | $0.31 | $-0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $429.5M | $4.5B |
| Total DebtLower is stronger | — | $836.4M |
| Stockholders' EquityBook value | $779.3M | $4.4B |
| Total Assets | $2.2B | $8.2B |
| Debt / EquityLower = less leverage | — | 0.19× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $429.5M | $4.5B | ||
| Q3 25 | $463.4M | $4.0B | ||
| Q2 25 | $342.1M | $2.8B | ||
| Q1 25 | $260.9M | $2.5B | ||
| Q4 24 | $290.8M | $2.6B | ||
| Q3 24 | $350.3M | $2.7B | ||
| Q2 24 | $327.7M | $2.6B | ||
| Q1 24 | $337.3M | $2.8B |
| Q4 25 | — | $836.4M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $779.3M | $4.4B | ||
| Q3 25 | $775.5M | $4.1B | ||
| Q2 25 | $765.5M | $3.8B | ||
| Q1 25 | $745.4M | $3.5B | ||
| Q4 24 | $712.7M | $3.3B | ||
| Q3 24 | $704.6M | $3.4B | ||
| Q2 24 | $678.9M | $3.4B | ||
| Q1 24 | $653.5M | $3.4B |
| Q4 25 | $2.2B | $8.2B | ||
| Q3 25 | $2.2B | $7.6B | ||
| Q2 25 | $1.4B | $6.3B | ||
| Q1 25 | $1.3B | $5.8B | ||
| Q4 24 | $1.4B | $5.9B | ||
| Q3 24 | $1.3B | $5.8B | ||
| Q2 24 | $1.3B | $5.7B | ||
| Q1 24 | $1.2B | $5.7B |
| Q4 25 | — | 0.19× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.9M | $417.3M |
| Free Cash FlowOCF − Capex | $-6.0M | $379.8M |
| FCF MarginFCF / Revenue | -0.6% | 25.4% |
| Capex IntensityCapex / Revenue | 0.3% | 2.5% |
| Cash ConversionOCF / Net Profit | -0.44× | 6.28× |
| TTM Free Cash FlowTrailing 4 quarters | $104.5M | $941.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.9M | $417.3M | ||
| Q3 25 | $10.0M | $402.6M | ||
| Q2 25 | $90.9M | $263.6M | ||
| Q1 25 | $16.6M | $44.1M | ||
| Q4 24 | $-10.9M | $75.2M | ||
| Q3 24 | $34.0M | $188.4M | ||
| Q2 24 | $23.2M | $-95.6M | ||
| Q1 24 | $6.0M | $-308.6M |
| Q4 25 | $-6.0M | $379.8M | ||
| Q3 25 | $7.4M | $354.5M | ||
| Q2 25 | $89.5M | $219.8M | ||
| Q1 25 | $13.6M | $-12.3M | ||
| Q4 24 | $-13.5M | $-17.3M | ||
| Q3 24 | $31.7M | $54.7M | ||
| Q2 24 | $20.4M | $-205.5M | ||
| Q1 24 | $5.6M | $-465.1M |
| Q4 25 | -0.6% | 25.4% | ||
| Q3 25 | 0.8% | 25.1% | ||
| Q2 25 | 13.7% | 16.7% | ||
| Q1 25 | 2.2% | -1.1% | ||
| Q4 24 | -2.0% | -1.5% | ||
| Q3 24 | 6.6% | 5.5% | ||
| Q2 24 | 4.2% | -22.1% | ||
| Q1 24 | 1.4% | -61.9% |
| Q4 25 | 0.3% | 2.5% | ||
| Q3 25 | 0.3% | 3.4% | ||
| Q2 25 | 0.2% | 3.3% | ||
| Q1 25 | 0.5% | 5.0% | ||
| Q4 24 | 0.4% | 8.2% | ||
| Q3 24 | 0.5% | 13.3% | ||
| Q2 24 | 0.6% | 11.8% | ||
| Q1 24 | 0.1% | 20.8% |
| Q4 25 | -0.44× | 6.28× | ||
| Q3 25 | 26.69× | 3.22× | ||
| Q2 25 | 9.65× | 2.79× | ||
| Q1 25 | 2.48× | 34.71× | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.11× | — | ||
| Q2 24 | 1.21× | — | ||
| Q1 24 | 0.40× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASTH
| Medicare | $542.4M | 57% |
| Commercial | $99.1M | 10% |
| Care Delivery | $92.1M | 10% |
| Care Enablement | $78.9M | 8% |
| Other Third Parties | $58.0M | 6% |
| Health Care Patient Service | $39.8M | 4% |
| Health Care Other | $25.5M | 3% |
| Other | $12.1M | 1% |
| Management Service | $10.3M | 1% |
ONC
Segment breakdown not available.
